Evaluation of Azithromycin-Chloroquine Combination to Prevent Malaria with Weekly Dosing
Abstract
Malaria remains the top infectious disease threat facing the U.S. military in many forward operating environments. Current FDA approved weekly chemoprophylaxis options have contraindications that can limit prescribing. In this open label study 18 healthy volunteers, aged 18-50 years (inclusive), were randomly assigned to receive either 300 mg CQ or 300 mg CQ and 2 gm azithromycin (CQAZ) of directly observed therapy, weekly for 3 weeks prior to undergoing mosquito bite challenge with chloroquine-resistant Plasmodium falciparum. The primary objective of this study was to assess the safety and efficacy of a weekly CQAZ regimen for prophylaxis against CQ resistant Plasmodium falciparum. Secondary objectives were to assess the tolerability and pharmacokinetics of the regimen. Given the high rate of side effects and poor efficacy when administered for 3 weeks before and after challenge, the combination of weekly chloroquine and azithromycin is a suboptimal regimen combination for weekly malaria chemoprophylaxis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2020
- Accession Number
- AD1118219
Entities
People
- Jeffrey Livezey
Organizations
- Uniformed Services University of the Health Sciences
- Walter Reed Army Institute of Research